Medindia LOGIN REGISTER
Medindia
Advertisement

Europe Breast Cancer Screening Market (Mammography, MRI & Ultrasound) Forecast to 2022

Wednesday, June 28, 2017 Cancer News
Advertisement
LONDON, June 28, 2017 /PRNewswire/ -- Europe Breast Cancer Screening Market will be less than US$ 8 Billion by the end of year 2022. Breast cancer is one of the most dangerous diseases in the Europe region. Its incidence rate in Europe was 92.9 women per 100,000 women and mortality rate was 23.1 per 100,000 women. So, most of the countries of Europe has adopted or in the process to adopt breast cancer screening in their national cancer screening programs. Mammography screening is most commonly used as breast cancer screening method in Europe. Download the full report: https://www.reportbuyer.com/product/4962733/Germany has the Highest Market Share in Breast Cancer Screening Market, but it will lose its Market Leader Position to United Kingdom in Future Germany is the clear winner in the breast cancer screening market as it has huge women population, advanced healthcare infrastructure and government supported screening programs. Under the programs, all women age between 50-69 years are eligible for free breast cancer screening test in every two years. Under this program eligible woman gets a letter from the regional mammography program center to participate in the breast cancer screening program.Germany will maintain their Dominating Position in Europe Breast Cancer Ultrasound Screening MarketDue to strong healthcare expending power and increasing breast cancer awareness among the women, Germany is forecast to hold its dominating place in Europe Breast Cancer Screening Market. Presently, Germany, Italy and Spain are steadily losing their market share on comparison to this all other countries such as United Kingdom, France, Switzerland, Norway and Netherlands ultrasound screening market share is expected to grow in the forecasting period 2017-2022.Europe Breast Cancer Screening (Mammography, MRI & Ultrasound) Market & Forecast to 2022 is the 2nd Report published by Renub Research on Breast Cancer Screening Market. The report analyzes the Europe Breast Cancer Mammography Screening Market, Breast Cancer MRI Screening Market and Breast Cancer Ultrasound Screening Market. This report studies separate comprehensive analytics for the 8 countries: United Kingdom, France, Germany, Italy, Spain, Netherlands, Norway and Switzerland This 122 page report with 120 Figures and 2 Tables provides a complete analysis of top 8 courtiers of Europe Breast Cancer Screening Market. All the 8 countries in the report have been studied from 7 viewpoints.• Countries Breast Cancer Mammography Screening Population Scenario and Forecast • Countries Breast Cancer MRI & Ultrasound Screening Population Scenario and Forecast • Countries Breast Cancer Mammography Screening Market and Forecast • Countries Breast Cancer MRI Screening Market and Forecast • Countries Breast Cancer Ultrasound Screening Market and Forecast • Countries Breast Cancer Screening Market and Forecast • Worldwide Breast Cancer Screening Market and Forecast All the 8 Countries Studied in the Report are as Follows 1. United Kingdom2. France3. Germany4. Italy5. Spain6. Netherlands7. Norway8. SwitzerlandDownload the full report: https://www.reportbuyer.com/product/4962733/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected]  Tel: +44 208 816 85 48 Website: www.reportbuyer.com 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/europe-breast-cancer-screening-market-mammography-mri--ultrasound-forecast-to-2022-300481148.html

SOURCE ReportBuyer

Sponsored Post and Backlink Submission


Latest Press Release on Cancer News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close